Mavrostobart vs Mupadolimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: CD73 · full Non-Small Cell Lung Cancer pipeline

Mavrostobart

Developed by Phanes Therapeutics

monoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT05431270 (registry estimate)

No aligned efficacy figure on record for this race.

Mupadolimab

Developed by Corvus Pharmaceuticals and partners

Phase 1 in Non-Small Cell Lung Cancermonoclonal antibody
Weak signal

NCT03454451 · Phase 1 · completed

Although the registry labels the allocation as randomized, none of the six groups received a placebo or an inactive comparator, and there was no blinding, so this functions as an open-label dose-escalation and combination study rather than a controlled comparison. The main goals were safety, tolerated dose, and drug levels. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Incidence of dose-limiting toxicities (DLTs) of CPI-006 as a single agent and in combination with ciforadenant and with pembrolizumab. (From start of treatment to end of treatment, up to 36 months); Incidence of treatment-emergent adverse events as assessed by NCI CTCAE v.4.03, of CPI-006 as single agent and in combination with ciforadenant and with pembrolizumab. (From start of treatment to end of treatment, up to 36 months); Identify the MDL(maximum dose level) of single agent CPI-006 (From start of treatment to end of treatment, up to 36 months): Mupadolimab (CPI-006) monotherapy/combination in advanced cancers: doses up to 18 mg/kg tolerated without DLTs; minor tumor regression (below PR threshold) in 5 patients with prior PD.

Result source: NCT03454451

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMavrostobartMupadolimab
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
Duration of response, median—Not reported—Not reported

PFS, median

Mavrostobart
—Not reported
Mupadolimab
—Not reported

OS, median

Mavrostobart
—Not reported
Mupadolimab
—Not reported

ORR

Mavrostobart
—Not reported
Mupadolimab
—Not reported

Duration of response, median

Mavrostobart
—Not reported
Mupadolimab
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Mavrostobart: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Mupadolimab
Mupadolimab (CPI-006) monotherapy/combination in advanced cancers: doses up to 18 mg/kg tolerated without DLTs; minor tumor regression (below PR threshold) in 5 patients with prior PD. NCT03454451 · Phase 1 · design grade: weak · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mavrostobart's landscape · Mupadolimab's landscape